Genentech Announces FDA Approval of Xofluza (baloxavir marboxil) for People at High Risk of Developing Influenza-Related Complications

South San Francisco, CA -- October 17, 2019 -- Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza™ (baloxavir marboxil)...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news